President, CEO & Director
Jay Hagan currently serves as president, CEO and director of Ambros Therapeutics, a clinical-stage biotechnology company seeking a potential breakthrough therapy for patients suffering from complex regional pain syndrome type 1 (CRPS-1). Prior to Ambros, Jay was the president, CEO and director of Regulus Therapeutics from 2016 until the company’s $1.7 billion acquisition by Novartis in 2025. He previously worked as executive vice president and chief financial and business officer at Orexigen Therapeutics (acquired by Nalpropion Pharmaceuticals). Jay holds an MBA from the D’Amore-McKim School of Business at Northeastern University.